Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 HKD | +2.94% | 0.00% | -4.11% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.11% | 176M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+53.04% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma's Liver Treatment Reduces Fat in 9 of 10 Participants During Phase 2 Trial